GET A PIECE OF EO2 CONCEPTS
EO2’s CDO therapy system is an enhanced wound care solution that improves patient outcomes when recovering from chronic wounds, skin injuries, or surgeries. It utilizes the continuous delivery of oxygen directly to the tissue, which has been shown to achieve faster healing, reduced pain levels, and overall improved skin health.*
EO2’s addressable market encompasses two multibillion dollar divisions. Globally, the chronic wound care sector is estimated to be worth over $20B,*while the aesthetics and cosmetic surgery industry is valued at $63.4B and expected to exhibit nearly double digit CAGR between now and 2030.*
As an industry innovator, EO2 is focused on continual product testing, research, development, and design, in collaboration with key opinion leaders and medical professionals. Our unique position in an expanding marketplace is secure through 2038, protected by numerous national and international patents, as well as additional patents pending.
For patients recovering from wounds (i.e. ulcers and burns), amputations, and cosmetic/restorative surgeries, oxygen is one of the most vital elements in the wound-healing process (source). Understanding this, EO2 has developed proprietary technology that allows pure, humidified oxygen to be continuously diffused directly into the tissue, thereby creating an optimal environment for skin repair and restoration. The OxyGeni is an all-inclusive system that offers oxygen generation, wound monitoring, oxygen diffusion dressings, and accessories, all in one lightweight and discrete wearable device.
The Problem & Our Solution
A common obstacle to proper healing of wounds is a lack of oxygen, caused by blocked or damaged blood pathways. Oxygen via the bloodstream is what provides nourishment to the skin and dermal tissues, fueling important processes like collagen formation, cellular regeneration, antibacterial activity, and repair. When the body doesn’t have access to sufficient levels of oxygen, it becomes much harder to carry out these essential functions. However, most existing wound care options involve covering damaged skin, thereby blocking direct flow of oxygen to the tissue.
As a solution, EO2 has developed a system that not only restores oxygen levels, yet also enhances those levels beyond the body’s normal capacity. Using our wearable device, patients receive advanced wound care anywhere, anytime, and are able to accelerate the entire healing process. Additionally, because CDO therapy has benefits for reducing pain and inhibiting the formation of scars, the technology helps to restore quality of life. Positive outcomes from treatment with OxyGeni range from improving aesthetic appearance to preventing amputation.
The Market & Our Traction
Over the last several years, EO2 has been making significant progress across many verticals. In clinical trials, the company’s technology has been substantiated by multiple studies, with peer-reviewed papers published by notable national and international industry leaders. Meanwhile, on the marketing side, we’ve seen mass social media response to the performance of our products for patients, especially in the cosmetic procedures market.
As a result of our success in these areas, EO2 has seen a robust increase in sales. Within the plastics and aesthetics market, we’ve demonstrated triple-digit YOY growth and in Canada, the company has moved from unpaid trials to payment models in six provinces. By creating products designed to accommodate today’s telehealth models, we are enabling patients to be more involved in their own care through mobile app design, automated product delivery, and AI-driven communication.
Although EO2 Concepts initially developed solutions for the chronic wound care market, the company has exciting opportunities to expand into other markets based on the science of oxygen therapy’s efficacy and the feedback of medical users. Our newest and fastest-growing market is in aesthetic and reconstructive surgery, as the technology can be used to facilitate healing following face lifts, breast reductions, laser facials, and cosmetic injectables.
Chronic wounds affect millions of patients each year and the costs to our healthcare system for diabetic foot complications alone are comparable to all cancers combined (source). Complications from a wound can last months or years, sometimes resulting in amputations, and severely impacting quality of life for patients. Having developed a system that can improve recovery outcomes, in a more accessible and affordable format, EO2’s vision is to bring our technology to the medical community and become the standard of care across multiple segments. Be a part of our success story by investing on Start Engine!
EO2 Concepts is an advanced wound healing technology company leveraging continuous diffusion of oxygen (CDO) therapy to commercialize innovative medical modalities. The company’s primary in-market product is OxyGeni, a wearable device designed to heal wounds to complete closure while simultaneously supporting skin and soft tissue restoration, shortening recovery time, reducing pain, and minimizing the formation of scar tissue in the process.
President, CEO, Board Member
Ken Melani, MD
Chief Financial Officer & Secretary
Business Manager and Assistant Secretary
Exec. VP of Sales and Marketing, Board Member
Chairman of the Board of Directors
James P. Daley
Director of Operations
Cyndi Gilliam, BSN, RN, FACCWS
Director of Clinical Affairs
Quality Assurance Manager
Maximum Number of Shares Offered subject to adjustment for bonus shares
Most Recent Fiscal Year-End
Prior Fiscal Year-End
Cash & Cash Equivalents
Revenue & Sales
Costs of Goods Sold
*Maximum number of shares offered subject to adjustment for bonus shares. See Bonus info below.
o First 72 hours – 10% Super Early Bird Bonus
o First week (days 4-7) – 8% Very Early Bird Bonus
o First 3 weeks (week 2 & 3) - 5% Early Bird Bonus
o $600+ – 3% bonus shares , Member, Contributing to enabling advanced healing with oxygen.
o $1,500+ – 5% bonus shares, Leader, Leading the way in oxygen healing solutions.
o $5,000+ – 8% bonus shares, Innovator, Bringing next generation solutions to oxygen delivery and patient monitoring.
o $15,000+ – 10% bonus shares, Visionary, Ensuring the long-term growth and innovation in oxygen solutions for health care.
Loyalty Bonus - 10% Bonus Shares for Friends and Family
*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonus shares from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed.
Electrochemical Oxygen Concepts, Inc. will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.
This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Series A Non-Voting Preferred Stock at $1.59/ share, you will receive 110 shares of Series A Non-Voting Preferred Stock, meaning you'll own 110 shares for $159. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.
This 10% Bonus is only valid during the investor's eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.
Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and the time of offering elapsed (if any). Eligible investors will also receive the Owner’s Bonus and an the Loyalty bonus in addition to the aforementioned bonus.
Irregular Use of Proceeds
The Company will not incur irregular use of proceeds.
Members get an extra 10% shares in addition to rewards below!
a month ago
a month ago
3 months ago
4 months ago
4 months ago
4 months ago
5 months ago
5 months ago
6 months ago
6 months ago
Cancel anytime before 48 hours before a rolling close or the offering end date.
We want you to succeed and get the most out of your money by offering rewards and memberships!
Your info is your info. We take pride in keeping it that way!
Invest in over 200 start-ups and collectibles!
With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.
With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.
At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.
Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.
StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.
For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.
For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.
Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.
Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.
Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.